Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023-Reference-Cited by-同舟云学术

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023

Published:2023-09-04 Issue:9 Volume:30 Page:8172-8185
ISSN:1718-7729
Container-title:Current Oncology
language:en
Short-container-title:Current Oncology

Author:

Al-Mansor Essa¹,Mahoney Meghan²,Chenard-Poirier Maxime³,Ramjeesingh Ravi⁴^ORCID,Nair Vimoj¹^ORCID,Kennedy Erin⁵,Locke Gordon¹^ORCID,Welch Stephen⁶,Berry Scott⁷,Couture Felix³,Elimova Elena⁸,Pollett Aaron⁵^ORCID,Mahmud Aamer⁷,Wilson Brooke⁷,Armstrong Dawn²^ORCID,Falkson Conrad⁷,Asmis Timothy¹,Vickers Michael¹,Goodwin Rachel¹

Affiliation:

1. The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada

2. Faculty of Medicine, Memorial University of Newfoundland, Dr. H. Bliss Murphy Cancer Centre, St. John’s, NL A1B 3V6, Canada

3. CHU de Québec—Université Laval, Québec, QC G1R 2J6, Canada

4. Queen Elizabeth II Health Sciences Centre, Halifax, NS B3H 2Y9, Canada

5. Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada

6. London Regional Cancer Program, London, ON N6A 5W9, Canada

7. Department of Oncology, Cancer Centre of Southeastern Ontario, Queen’s University, Kingston, ON K7L 5P9, Canada

8. Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada

Abstract

The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023 was held in Quebec City, Quebec 2–4 February 2023. The purpose of the conference was to develop consensus statements on emerging and evolving treatment paradigms. Participants included Canadian medical oncologists, radiation oncologists, pathologists and surgical oncologists from across Ontario, Quebec, and the Atlantic provinces. Consensus statements were developed following rapid review presentations and discussion of available literature. The recommendations proposed here represent the consensus opinions of physicians involved in the care of patients with gastrointestinal malignancies who participated in this meeting.

Funder

Astellas

AstraZeneca

Organon

Pfizer

Amgen

Eisai

Viatris

Novartis

Merck

BMS

Ipsen

Taiho Pharma

Incyte

Publisher

MDPI AG

Link

https://www.mdpi.com/1718-7729/30/9/593/pdf

Reference52 articles.

1. (2023, February 15). Tissue-Agnostic Cancer Therapy: DNA Mismatch Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Solid Tumors—UpToDate. Available online: https://www.uptodate.com/contents/tissue-agnostic-cancer-therapy-dna-mismatch-repair-deficiency-tumor-mutational-burden-and-response-to-immune-checkpoint-blockade-in-solid-tumors?search=mmr%20deficiency&source=search_result&selectedTitle=1~55&usage_type=default&display_rank=1.

2. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates;Brahmer;J. Clin. Oncol.,2010

3. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer;Shiu;N. Engl. J. Med.,2020

4. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study;Lenz;J. Clin. Oncol.,2022

5. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164;Le;J. Clin. Oncol.,2020